Regeneron's Eylea grabs key new use in diabetic retinopathy; Merck adds $10B to buyback plan;

@FiercePharma: Why All Those Testosterone Ads Constitute Disease Mongering. Forbes article | Follow @FiercePharma

@EricPFierce: ICYMI from FiercePharmaManufacturing: Former Boehringer Ingelheim workers whiplashed by China firm's plans for Virginia API plant. Article | Follow @EricPFierce

@CarlyHFierce: Which diseases are driving drug spending hikes? It's not just hep C. Story | Follow @CarlyHFierce

> Regeneron ($REGN) and Bayer's eye drug Eylea nabbed a new indication in diabetic retinopathy, the most common cause of eye disease in diabetics; the drug's head-to-head rival, Lucentis, won the same approval last month. Release

> Merck & Co. ($MRK) added another $10 billion to its ongoing stock buyback program. Report

> Jordan-based Hikma Pharmaceuticals is planning to meet with investors about a potential dollar-denominated bond issue. Report

> The FDA gave its blessing to an inhaled anthrax treatment, Anthrasil, from Emergent BioSolutions ($EBS), which developed the drug under contract with the U.S. government. Report

> Cosmo Pharmaceuticals, the drugmaker Endo ($ENDP) had planned to buy last year only to abandon the deal, saw 2014 revenue grow by 41.2% to €79 million. Report

Medical Device News

@FierceMedDev: French cancer Dx company born after management buyout at Qiagen unit. FierceDiagnostics story | Follow @FierceMedDev

@VarunSaxena2: ICYMI: Does the FDA overregulate devices? Experts weigh in. More | Follow @VarunSaxena2

@EmilyWFierce: Cepheid got FDA emergency use authorization for its rapid Ebola test. Release | Follow @EmilyWFierce

> Novartis rides med tech wave with new digital projects. Item

> Pennsylvania surgical tools manufacturing plant scheduled for closure, 250 layoffs planned. Article

Biotech News

@FierceBiotech: Cellectis upscales IPO toward $200M as CAR-T fever continues. Report | Follow @FierceBiotech

@JohnCFierce: ICYMI: Not giving up day job, but interviewing @Asthika from Bloomberg Intelligence on biotech market was fun. Watch | Follow @JohnCFierce

@DamianFierce: Last night's Jeopardy question about CAR-T means this is definitely a bubble, right? | Follow @DamianFierce

> AstraZeneca buys into Harvard's stem cell tech for diabetes R&D. More

> GlaxoSmithKline mounts an open casting call for R&D starlets. Article

> Novartis chief: Sometimes you have to kill your R&D darlings. Story

Biotech Research News

> Concert Pharma spotlights a positive rat study for antiseizure drug. Report

> Duke/NUS team says new combo has promise for mutant-RAS cancers. More

> CMV-based vaccine could help eliminate the threat of Ebola from apes. Story

> Stem cell advance may assist new therapies for anemia, leukemia. Item

> Targeted mitochondrial attack destroys glioma cells in preclinical study. Article

Diagnostics News

> Foundation Medicine reveals C-suite and board metamorphosis. Article

> French cancer Dx company born after management buyout at Qiagen unit. Story

> GE Healthcare's pathology arm to use Omnyx's software for digital analysis of specimens. More

> Dako strikes another cancer companion Dx deal with Amgen. Item

> Roche joins forces with Sigma-Aldrich to distribute biochemical reagents. Article

Pharma Marketing News

> Psoriasis data wars heat up at AAD with Novartis, Boehringer studies. Article

> Were Low-T ads 'disease mongering'? Two experts say yes. Story

> The 2014 DTC ads that made the grade. More

> Pharma's ad spend vaults to $4.5B, with big spender Pfizer leading the way. Article

> Sanofi aims for that sweet smell of success with spring Nasacort campaign. Report

And Finally... Many doctors don't tell their patients when they diagnose Alzheimer's. Report